The second model is mainly observed in MLH1 and MSH2 mutation carriers and is typically characterized by inactivation of tumor suppressors involved in the WNT pathway, predominantly TGFBR2 and RNF43, due to frameshift mutations within microsatellites in the corresponding genes [138,147]. The gene discussed is MLH1; the disease is neoplasm.